[Translation] A pivotal registration phase III clinical study of Orebatinib combined with chemotherapy versus imatinib combined with chemotherapy in the treatment of patients with newly diagnosed Ph chromosome-positive acute lymphoblastic leukemia (Ph+ALL)
评估奥雷巴替尼联合化疗对比伊马替尼联合化疗在新诊断Ph+ALL受试者中的有效性和安全性。
[Translation] To assess the efficacy and safety of orebatinib plus chemotherapy versus imatinib plus chemotherapy in subjects with newly diagnosed Ph+ ALL.